A Phase 3 interventional study of Aripiprazole depot 300 or 400 mg and Aripiprazole 10-30 mg orally in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 98 sites in 15 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 4th largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 3, and was the 51st registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 937 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 111 interventional ones that give a count, is one of 4 that started in 2008, is one of 50 in phase 3, and was the 26th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia
The trial is designed into three treatment phases. Phase 1 is designed to allow for a subject to be converted from the current anti-psychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2 the subject will be stabilized on oral non-generic aripiprazole monotherapy. Once the subject is stabilized in Phase 2 (oral stabilization phase from minimum 8 weeks to maximum 28 weeks), they are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. During Phase 3, the subject will be assessed for exacerbation of psychotic symptoms and impending relapse for up to 38 weeks.
This will be a randomized, double-blind, active-controlled study consisting of a screening phase and 3 treatment phases. Eligibility will be determined during a screening phase of 2 to 42 days. Subjects currently receiving oral treatment with an anti-psychotic other than non-generic aripiprazole will enter Phase 1, and subjects with a lapse in aripiprazole or other anti-psychotic treatment at the time of study entry ("lapse" defined as > 3 consecutive days without medication) will enter directly into Phase 2.
During Phase 1 (oral conversion), subjects will be cross-titrated during weekly visits from other anti-psychotics to oral non-generic aripiprazole monotherapy over a minimum of 4 weeks and a maximum of 6 weeks. During Phase 2 (that will be a minimum of 8 weeks and a maximum of 28 weeks in duration), subjects will be assessed bi-weekly and stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria are met at Phase 2, subjects are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. Subjects will be randomized with a 2:2:1 (aripiprazole IM depot 300-400 mg monthly, oral aripiprazole 10-30 mg daily, aripiprazole IM depot 25-50 mg monthly). During Phase 3 subjects will be assessed for impending relapse/exacerbation of psychotic symptoms. If a subject is identified with impending relapse/exacerbation of psychotic symptoms, they will be withdrawn from the trial and given the opportunity to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549). Alternatively, any subject that discontinues in Phase 3 (up to and including Week 38) will have the option to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549).
The enrollment figure includes re-screened patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
Drug: Aripiprazole depot 300 or 400 mg · Drug: Placebo tablets
Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
Drug: Aripiprazole 10-30 mg orally · Drug: Placebo depot
Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
Drug: Aripiprazole depot 25 or 50 mg · Drug: Placebo tablets
Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
Also known as: Abilify
Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
Also known as: Abilify
Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
Also known as: Abilify
Placebo depot was supplied in lyophilized vials.
Placebo tablets were identical in appearance to the aripiprazole tablets.
Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26
A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.
Time frame: Baseline to Week 26
Time to Exacerbation of Psychotic Symptoms/Impending Relapse
Time frame: Baseline to the end of the study (Week 38)
Percentage of Responders up to Week 38
A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.
Time frame: Baseline to the end of the study (Week 38)
Percentage of Patients Achieving Remission
A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).
Time frame: Baseline to the end of the study (Week 38)
| Milestone | All Patients | Aripiprazole Depot 300 or 400 mg | Aripiprazole 10-30 mg Orally | Aripiprazole Depot 25 or 50 mg |
|---|---|---|---|---|
| Started | 709 | 0 | 0 | 0 |
| Completed | 614 | 0 | 0 | 0 |
| Not completed | 95 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 0 | 0 |
| Withdrew: Sponsor discontinued trial | 8 | 0 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawn by investigator | 14 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 38 | 0 | 0 | 0 |
| Withdrew: Adverse event | 18 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy with adverse event | 9 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy without adverse event | 2 | 0 | 0 | 0 |
| Milestone | All Patients | Aripiprazole Depot 300 or 400 mg | Aripiprazole 10-30 mg Orally | Aripiprazole Depot 25 or 50 mg |
|---|---|---|---|---|
| Started | 842 | 0 | 0 | 0 |
| Completed | 662 | 0 | 0 | 0 |
| Not completed | 180 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 17 | 0 | 0 | 0 |
| Withdrew: Sponsor discontinue trial | 19 | 0 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 15 | 0 | 0 | 0 |
| Withdrew: Withdrawn by investigator | 21 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 55 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 21 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy with adverse event | 20 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy without adverse event | 10 | 0 | 0 | 0 |
| Milestone | All Patients | Aripiprazole Depot 300 or 400 mg | Aripiprazole 10-30 mg Orally | Aripiprazole Depot 25 or 50 mg |
|---|---|---|---|---|
| Started | 0 | 265 | 266 | 131 |
| Completed | 0 | 196 | 178 | 61 |
| Not completed | 0 | 69 | 88 | 70 |
| Withdrew: Lost to follow-up | 0 | 4 | 10 | 6 |
| Withdrew: Met withdrawal criteria | 0 | 4 | 6 | 5 |
| Withdrew: Withdrawn by investigator | 0 | 8 | 12 | 8 |
| Withdrew: Withdrew consent | 0 | 21 | 29 | 14 |
| Withdrew: Protocol deviation | 0 | 2 | 3 | 1 |
| Withdrew: Adverse event without impending relapse | 0 | 8 | 7 | 7 |
| Withdrew: Impending relapse with adverse event | 0 | 13 | 12 | 17 |
| Withdrew: Impending relapse without adverse event | 0 | 9 | 9 | 12 |
A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score \> 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score \> 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.
| Percentage of patients | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase |
|---|---|---|---|
| Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26 | 7.12 (1.62 to —) | 7.76 (1.72 to —) | 21.80 (3.97 to —) |
| Days | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase |
|---|---|---|---|
| Time to Exacerbation of Psychotic Symptoms/Impending Relapse | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.
| Percentage of patients | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase |
|---|---|---|---|
| Percentage of Responders up to Week 38 | 89.8 | 89.4 | 75.2 |
A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).
| Percentage of patients | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase |
|---|---|---|---|
| Percentage of Patients Achieving Remission | 48.8 | 53.2 | 59.7 |
Collected over Adverse events were reported from the time of the signing of informed consent until the end of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Patients - Conversion Phase | — | 21/709 (3%) | 140/709 (19.7%) |
| All Patients - Oral Stabilization Phase | — | 39/842 (4.6%) | 177/842 (21%) |
| Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | — | 15/265 (5.7%) | 161/265 (60.8%) |
| Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | — | 15/266 (5.6%) | 142/266 (53.4%) |
| Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase | — | 11/131 (8.4%) | 74/131 (56.5%) |
| Event | All Patients - Conversion Phase | All Patients - Oral Stabilization Phase | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase |
|---|---|---|---|---|---|
| Psychotic disorderPsychiatric disorders | 8/709 | 15/842 | 4/265 | 2/266 | 4/131 |
| SchizophreniaPsychiatric disorders | 3/709 | 9/842 | 5/265 | 2/266 | 3/131 |
| Suicidal ideationPsychiatric disorders | 2/709 | 4/842 | 1/265 | 0/266 | 1/131 |
| SepsisInfections and infestations | 0/709 | 0/842 | 0/265 | 0/266 | 1/131 |
| ConvulsionNervous system disorders | 0/709 | 0/842 | 0/265 | 0/266 | 1/131 |
| Neuroleptic malignant syndromeNervous system disorders | 0/709 | 0/842 | 0/265 | 0/266 | 1/131 |
| Completed suicidePsychiatric disorders | 0/709 | 0/842 | 0/265 | 0/266 | 1/131 |
| Organising pneumoniaRespiratory, thoracic and mediastinal disorders | 0/709 | 0/842 | 0/265 | 0/266 | 1/131 |
| Schizophrenia, paranoid typePsychiatric disorders | 0/709 | 1/842 | 0/265 | 2/266 | 0/131 |
| AgitationPsychiatric disorders | 0/709 | 1/842 | 1/265 | 0/266 | 0/131 |
| Event | All Patients - Conversion Phase | All Patients - Oral Stabilization Phase | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase |
|---|---|---|---|---|---|
| InsomniaPsychiatric disorders | 78/709 | 87/842 | 31/265 | 37/266 | 18/131 |
| Weight increasedInvestigations | 5/709 | 23/842 | 24/265 | 35/266 | 7/131 |
| Back painMusculoskeletal and connective tissue disorders | 1/709 | 14/842 | 10/265 | 14/266 | 15/131 |
| HeadacheNervous system disorders | 39/709 | 44/842 | 26/265 | 30/266 | 7/131 |
| AkathisiaNervous system disorders | 36/709 | 63/842 | 28/265 | 18/266 | 11/131 |
| Weight decreasedInvestigations | 10/709 | 25/842 | 26/265 | 16/266 | 12/131 |
| NasopharyngitisInfections and infestations | 17/709 | 18/842 | 21/265 | 25/266 | 9/131 |
| AnxietyPsychiatric disorders | 28/709 | 35/842 | 19/265 | 13/266 | 10/131 |
| Injection site painGeneral disorders | 0/709 | 1/842 | 20/265 | 6/266 | 1/131 |
| Upper respiratory tract infectionInfections and infestations | 14/709 | 12/842 | 18/265 | 11/266 | 5/131 |
Baseline measures are based on the participants from the Depot Maintenance Phase.
| Age, Continuous(years) | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase | Total |
|---|---|---|---|---|
| Mean | 41.7 ± 10.4 | 41.2 ± 10.8 | 40.2 ± 9.6 | 40.7 ± 10.4 |
| Sex/Gender, Customized(Participants) | Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase | Aripiprazole 10-30 mg Orally - Depot Maintenance Phase | Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase | Total |
|---|---|---|---|---|
| Female | 105 | 98 | 53 | 256 |
| Male | 160 | 168 | 78 | 406 |
Ran from Sep 2008 to primary completion in Aug 2012, 47 months.
Results were first posted in Aug 2013, 1 year after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 47 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →